Akers Biosciences Inc (AKR)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | n/a |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 0.81 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | TTM | 2012E | 2013E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | ||||||||||
FINANCIAL BRIEF: For the six months ended 30 June 2012, Akers Biosciences, Inc. revenues decreased 28% to $787K. Net loss increased 22% to $1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Sales and Marketing Expenses increase from $149K to $323K (expense), Other Income decrease of 75% to $23K (income), Currency Gains/Loss decrease of 40% to $6K (income). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Jun '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 0 | 1 |
Akers Biosciences, Inc. (ABI) is focused on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main product is a disposable breathalyzer test that measures the blood alcohol content of the user. ABI’s portfolio is derived from four of the Company’s six platform technologies: Particle ImmunoFiltration Assay (PIFA), Micro Particle Catalyzed (MPC) Biosensor, Rapid Enzymatic Assay (REA) and Synthetic Macrocycle Complex (SMC). The core products marketed under the PIFA platform are the PIFA Heparin/PF4 Rapid Assay, a variety of rapid infectious disease screening tests, and the Battlefield Blood Transfusion Card.
Directors: Raymond Akers (Chmn.) , Thomas Nicolette (CEO) , Patrice McMorrow (VP) , Gary Rauch (Contr.) ,
No. of Employees: 4,000 No. of Shareholders: n/a
| Last Annual | December 31st, 2011 |
| Last Interim | June 30th, 2012 |
| Shares in Issue | 198,815,666 |
| Free Float | 136.6m (68.7%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | , THOROFARE, 08086, United States |
| Web | http://www.akersbiosciences.com |
| Phone | +1 856 8482116 |
| Contact | Raymond F. Akers (CEO) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Morison Cogen, LLP |
| Fri 12:25pm | Holding(s) in Company |
| 13th Jun | Extension of Agreement & $1.6m Subscription |
| 10th Apr | Trading Update |
| 27th Feb | Final Award of NF Mark |
| 19th Feb | Trading Update |
| 20th Dec '12 | Result of AGM |
Recent ↓
